The nationwide experiment will initially include around 100,000 volunteers.
The massive sum will buy out Kite Pharma, whose cancer therapy is expected to be among the first of its type approved by the FDA.
The massive sum will buy out Kite Pharma, whose cancer therapy is expected to be among the first of its type approved by the FDA.
Scientists hope that these devices will one day replace animal models of disease and help advance personalized medicine.
E. coli that make indoles protect older worms, flies, and mice from frailty.
A group of Danish obstetricians notes that the procedure carries risks and that there is little evidence supporting its benefits to the infant microbiome.
The infectious disease scientist spent seven years in the U.S. before returning home to establish a thriving center for research and help lead the fight against malaria.
A memory B cell response to Zika virus in dengue-infected patients produced antibodies that were poorly neutralizing in vitro and instead enhanced infection.
A review of several dozen hospitalized patients in Brazil finds neurological conditions, including inflammation of the brain and spinal cord, in addition to Guillain-Barre syndrome.
There is little evidence that full treatment durations discourage the development of drug-resistant bacteria.
In human cells, researchers deploy the genome editor to snip out toxic repetitive sequences.
The shotgun approach, typically thought to be the superior method, may substantially underestimate diversity in environments that have not already been classified, researchers find.